SECOND CONFERENCE OF IMMUTRAIN - COPENHAGEN



Immunotherapy of cancer; current status and future prospects

Draft Program

Wednesday 4th to Friday 6th October 2017

All days at: Panum Institute, University of Copenhagen - Faculty Club

Wednesday 4 th October 2017		
14.00	Lunch and arrival of conference attendants	
15.30	Opening address	
	SESSION I	
15.45	Title to be announced Sjoerd van der Burg, Head of Experimental Cancer Immunology and Therapy, University of Leiden, The Netherlands S.H.van der Burg@lumc.nl	
16.15	Radiation in combination with immunotherapy Inge Verbrugge, PhD, Division of Immunology, NKI, Netherlands i.verbrugge@nki.nl	
16.45	Strategy and behaviour in a group Mikkel Georg Schultz, Copenhagen Zoo mgs@zoo.dk	
17.30	Abstract presentation 1 of Early Stage Researcher (selected from abstracts)	
17.45	Beers and ESR Posters	
19.00	Dinner buffet	

Organised by Capital regionh of Copenhagen/Center for Cancer Immune Therapy (CCIT), Copenhagen University Hospital Herlev, Funded by the Innovative Training Network IMMUTRAIN project of the European Union's Horizon 2020 research and innovation programme, Marie Sklodowska-Curie grant agreement N° 641549









Thursday 5th October 2017

SESSION II 09.00 The Microbiome and anti-cancer immune responses **Laurence Zitvogel**, Tumour immunology and immunotherapy, Institut Gustave Roussy, France. laurence.zitvogel@orange.fr 09.30 Title to be announced Sine Reker Hadrup, Technical University of Denmark sirha@vet.dtu.dk 10.00 Coffee and posters 10.30 Title to be announced Niels Ødum, Department of Immunology and Microbiology, University of Copenhagen, DK ndum@sund.ku.dk 11.00 Title to be announced Hinrich Abken, Tumorgenetik & Immunologie, Klinik I fur Innere Medizin Und Zentrum für Molekulare Medizin Koln hinrich.abken@uk-koeln.de 11.30 Targeting of cancer specific carbohydrates by antibodies Hans Wandall, Faculty of Health and Medical Sciences, Centre for Glycomics, University of Copenhagen, DK hhw@sund.ku.dk 12.00 Lunch and poster session Supervisory Board Meeting for IMMUTRAIN Partners, working lunch (room 16.6.09) **SESSION III** 14.00 Targeting human cancer by a glycosaminoglycan binding malaria protein Ali Salanti, Department of Immunology and Microbiology, University of Copenhagen, DK salanti@sund.ku.dk 14.30 Coffee 15.00 Antibody engineering in drug discovery & development at Roche Claudio Sustmann, Roche Diagnostics GmbH claudio.sustmann@roche.com

Organised by Capital regionh of Copenhagen/Center for Cancer Immune Therapy (CCIT), Copenhagen University Hospital Herlev, Funded by the Innovative Training Network IMMUTRAIN project of the European Union's Horizon 2020 research and innovation programme, Marie Sklodowska-Curie grant agreement N° 641549









15.30	Abstract presentation 2 of Early Stage Researcher (selected from abstracts)
	Abstract presentation 3 of Early Stage Researcher (selected from abstracts)
16.00	T cells on the move: strategies to enhance access of T cells to solid tumors Sebastian Kobold , Klinikum der Universität München, Germany <u>sebastian.kobold@med.uni-muenchen.de</u>
16.30	Closed session for "IMMUTRAINERS"
19.00	Dinner buffet

Friday 6th October 2017

	Session IV
09.00	Title to be announced Daniel Hargbøl Madsen, Group Head, CCIT, DK daniel.hargboel.madsen@regionh.dk
09.30	Title to be announced Rolf Kiessling, Department of Oncology-Pathology, Karolinska Institute, Sweden. rolf.kiessling@ki.se
10.00	Title to be announced Manja Idorn, CCIT, DK manja.idorn@regionh.dk
10.30	Coffee
11.00	Tumor infiltrating lymphocytes in cancer treatment Marco Donia or Inge Marie Svane, CCIT, DK marco.donia@regionh.dk or inge.marie.svane@regionh.dk
11.30	Targeting of suppressive molecules by T cells Mads Hald Andersen, CCIT, DK mads.hald.andersen@regionh.dk
12.30	Thank you and goodbye and closing remarks Per thor Straten

Organised by Capital regionh of Copenhagen/Center for Cancer Immune Therapy (CCIT), Copenhagen University Hospital Herlev, Funded by the Innovative Training Network IMMUTRAIN project of the European Union's Horizon 2020 research and innovation programme, Marie Sklodowska-Curie grant agreement N° 641549





